BEVERLY, Mass., March 21 /PRNewswire/ -- CutisPharma, Inc. announced today that it has received Verified Accredited Wholesale Distribution (VAWD) accreditation from the National Association of Boards of Pharmacy (NABP). The VAWD program has been established by NABP to help protect the public from the threat of counterfeit drugs in the U.S. drug supply. Applicants undergo a thorough criteria compliance review, licensure verification, employee background checks, screening through the NABP Clearinghouse and a comprehensive on-site inspection conducted by NABP experts.
CutisPharma is a specialty pharmaceutical company that develops and commercializes “unit-of-use” prescription compounding kits. The Company distributes its compounding kits to National Wholesalers, Regional Distributors and Chain Drug stores. “We are pleased to receive VAWD accreditation from the National Association of the Boards of Pharmacy,” said Dr. Indu Muni, founder, chairman, and CEO of CutisPharma, Inc. “Our participation in the accreditation program further demonstrates our commitment towards providing quality prescription pharmaceutical products to our customers”.
CutisPharma currently has nine proprietary prescription compounding kits on the market: five progesterone suppository compounding kits, two testosterone kits, one hydrocortisone kit, and one Magic Mouthwash kit. Several more compounding kits are in the planning stages. FIRST(TM) Unit-of- Use Prescription Compounding Kits comply with United States Pharmacopeia (USP) Chapter < 795 >.
About CutisPharma
CutisPharma, Inc. based in Beverly, MA, is a privately held, specialty pharmaceutical company focusing on developing and commercializing value-added proprietary drug products and technologies in the prescription compounding sector of the pharmaceutical industry. Product line and development efforts, initially are focused on providing optimized, more efficient alternatives for the preparation of the nearly 8 million currently compounded prescriptions, by offering FIRST(TM) Unit-of-Use Prescription Compounding Kits. Use of these branded compounding kits is beneficial to all triad participants, namely physicians, pharmacists, and patients. A U.S. patent has been issued to the Company and additional patents are pending.
For more information please visit our website at http://www.cutispharma.com
About NABP
NABP is the independent, international, and impartial Association that assists its member boards and jurisdictions in developing, implementing, and enforcing uniform standards for the purpose of protecting the public health.
For more information about NABP or NABP’s VAWD program, visit NABP’s website at http://www.nabp.net
CutisPharma, Inc.
CONTACT: James Nagle, V.P. Business Development of CutisPharma, Inc.,+1-978-867-1010 x20
